Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
New research advances the development of personalized therapies for ovarian and breast cancer
August 19, 2011
A new study by Dr. Johanne Weberpals,
Dr. Jim Dimitroulakos
and others could help with the development of more personalized combination therapies for ovarian and breast cancer. Their research shows that compounds known as HDAC inhibitors can increase the sensitivity of ovarian and breast cancer cells to the common chemotherapy cisplatin, but this effect depends on how much BRCA1 protein is present in the cells. This research could lead to the development of a biomarker test to determine which patients are most likely to benefit from this combination therapy (which is currently being evaluated in clinical trials). See
Cancer Cell International
for details.
This research was supported by the Mitchell Family Fund, the National Ovarian Cancer Association, Cancer Care Ontario, the Canadian Institute for Health Research, the Ottawa Regional Cancer Foundation and the Department of Obstetrics and Gynecology, University of Ottawa. All research at OHRI is also supported by The Ottawa Hospital Foundation.